Lapatinib is a tyrosine kinase inhibitor (TKI) targeting the epidermal growth factor receptors ErbB1 and ErbB2, also known as HER2, which is approved for use in HER2 positive breast cancer. The gene discussed is EGFR; the disease is breast carcinoma.